FDA approves Sarclisa combination for multiple myeloma
Drug Discovery World
SEPTEMBER 27, 2024
It is approved in combination with bortezomib, lenalidomide, and dexamethasone for adults with who are not eligible for autologous stem cell transplant (ASCT). The efficacy of the treatment was evaluated in the IMROZ trial in patients with newly diagnosed multiple myeloma who were not eligible for ASCT.
Let's personalize your content